Gray Steven G, Mutti Luciano
Thoracic Oncology Research Group, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland.
Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA, USA.
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S100-S119. doi: 10.21037/tlcr.2019.11.23.
At the clinical level the role of immunotherapy in cancer is currently at a pivotal point. Therapies such as checkpoint inhibitors are being approved at many levels in cancers such as non-small cell lung cancer (NSCLC). Mesothelioma is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Various clinical trials for checkpoint inhibitors have been conducted in this rare disease, and suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer. Most recently approved as a salvage therapy in mesothelioma was granted in Japan, regulatory approval for their use in the clinic elsewhere lags. In this article we review the current pertinent clinical trials of immunotherapies in malignant mesothelioma, discuss the current issues that may affect the clinical outcomes of such therapies and further evaluate potential candidate new avenues that may become future targets for immunotherapy in this cancer.
在临床层面，免疫疗法在癌症治疗中的作用目前正处于关键阶段。诸如检查点抑制剂等疗法正在非小细胞肺癌（NSCLC）等多种癌症的多个层面获得批准。间皮瘤是一种与先前接触石棉相关的罕见孤儿病，预后不佳。针对这种罕见疾病已经开展了各种检查点抑制剂的临床试验，结果表明此类疗法可能对一部分该癌症患者起到治疗选择的作用。最近，在日本批准了将其作为间皮瘤的挽救疗法，而在其他地区临床使用的监管批准则滞后。在本文中，我们回顾了目前免疫疗法在恶性间皮瘤中的相关临床试验，讨论了可能影响此类疗法临床结果的当前问题，并进一步评估了可能成为该癌症未来免疫治疗靶点的潜在新途径。
